Navigation Links
Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Date:5/20/2008

n Americans who suffer from D-IBS and A-IBS.

About Asimadoline

Asimadoline is an orally administered small molecule that is a highly selective kappa opioid receptor agonist. Kappa opioid receptors are found in the digestive tract and are believed to play an important role in control of visceral pain and bowel motility. Asimadoline was originally discovered by Merck KGaA of Darmstadt, Germany. In 2005, Tioga purchased asimadoline from Merck and acquired by assignment all worldwide rights. Asimadoline has been tested in over 1100 subjects and has demonstrated a promising safety profile.

About Tioga

Tioga Pharmaceuticals, Inc. is a pharmaceutical company headquartered in San Diego, CA focused on developing novel treatments for gastrointestinal diseases. Tioga is currently planning Phase 3 development of asimadoline for the treatment of D-IBS and A-IBS and a Phase 2b trial of asimadoline for the treatment of functional dyspepsia. Both disorders represent a large unmet medical need and a substantial market opportunity. For more information, please visit http://www.tiogapharma.com.

Contact: David Urso, Chief Business Officer and General Counsel

Phone: 858-964-5021

Email: urso@tiogapharma.com

Media: Cory Tromblee, Porter Novelli Life Sciences

Phone: 617-897-8294

Email: ctromblee@pnlifesciences.com


'/>"/>
SOURCE Tioga Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Influenza will affect as many as 200,000 people this ... States as high as 49,000 people.  The main ... person to person in respiratory droplets of coughs and sneezes. ... but kills much fewer people each year than the Flu. ... including sweat, saliva, blood and other bodily fluids. The Ebola ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)...  Recently published clinical studies of Stretta for gastroesophageal ... of evidence. This data has led to significantly expanded ... for sufferers of refractory GERD. The ... therapy as a safe and effective GERD treatment has ... to nearly 50 million Americans. The new clinical studies ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2
...  With increasing demands for time spreading consumers thin — ... to and from their many appointments — running errands ... simpler for shoppers always on the go, Shopko announces ... to quickly and easily refill and manage their pharmacy ...
... SAN FRANCISCO, Jan. 10, 2012  The University of California, San ... Sanofi (EURONEXT: SAN and NYSE: SNY ) to ... could lead to new therapies for both type 1 and ... will bring together scientists in three UCSF labs with deep ...
Cached Medicine Technology:Shopko Launches Mobile Pharmacy App to Maximize Customer Convenience 2UCSF, Sanofi Collaborate to Find New Diabetes Cures 2UCSF, Sanofi Collaborate to Find New Diabetes Cures 3UCSF, Sanofi Collaborate to Find New Diabetes Cures 4UCSF, Sanofi Collaborate to Find New Diabetes Cures 5
(Date:10/22/2014)... (PRWEB) October 22, 2014 Isabel ... of Allied Health Professions (ASAHP) Conference on October 22-24 ... CEO will participate in a panel discussion on Technology ... , Isabel Healthcare provides a diagnostic decision support tool ... the diagnosis skills of students and clinical learners. The ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... 2014 Healthcare professionals who are ... education at home or on-the-go via laptops, tablets ... brand new, premium Seminar-on-Demand CE courses. The new ... 2,000 hours of CE course offerings, ... experience. With such a diverse library, there’s something ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... Salamon HealthDay Reporter TUESDAY, ... conventional in vitro fertilization (IVF) -- the incubation of embryos ... a device inside the vagina, new research suggests. Scientists ... called an INVOcell, might sharply cut costs for pricey IVF ... more accessible to those who don,t live near big-city assisted ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... 7 The Generic Pharmaceutical Association (GPhA) will discuss the ... leading healthcare market intelligence company, revealing that generic pharmaceutical utilization ... care system in the last decade., What: ... $734, ...
... Edward Downs has been named chief executive officer of Renaissance Hospital ... ... Houston, TX (PRWEB) May 7, 2009 -- Renaissance Healthcare ... executive officer of Renaissance Hospital Dallas. The appointment was effective May ...
... and Payroll Solutions Leader Introduces Industry-Pioneering Application , ... ... HRO®, a leader in human resources and payroll solutions, announces ... is a bold fusion of the company’s legacy GenevaPlus and ...
... & Sportsclub Association (IHRSA) and fitness professionals across ... meet with their Congressional members, asking for their ... barriers from exercise, and to reward Americans for ... Annual IHRSA Summit for a Healthier America, fitness ...
... other common factors in home health care can make ... used discount medical supplies. TheMedicalSupplyDepot.com announces the new Auto ... care individuals, set up their orders ahead of time ... skin care, incontinence or wound care items they need ...
... Pixantrone Named-Patient Program Initiated in Europe SEATTLE, May 7 ... reported recent accomplishments and financial results for the quarter ... half of 2009 was to initiate and complete the ... in our cost cutting efforts and raised much needed ...
Cached Medicine News:Health News:Edward Downs Named CEO of Renaissance Hospital Dallas 2Health News:Unicorn HRO Unveils iCON 2Health News:Fitness Industry Leaders Across the Nation Gather on Capitol Hill to Campaign for a Healthier America 2Health News:Fitness Industry Leaders Across the Nation Gather on Capitol Hill to Campaign for a Healthier America 3Health News:Fitness Industry Leaders Across the Nation Gather on Capitol Hill to Campaign for a Healthier America 4Health News:Home Health Care Supplies 'Order Themselves' with New Auto Reorder from TheMedicalSupplyDepot.com 2Health News:Home Health Care Supplies 'Order Themselves' with New Auto Reorder from TheMedicalSupplyDepot.com 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 2Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 4Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 5Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 6
... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... Tips - 2l - 200l. Reduces DNA and ... packaged completely by automation. RNAse & DNAse free. ... and 10 racks/cs. AVR2 is the Cell Rack ... the Stacked Rack packaged 96 tips/rack and 10 ...
Medicine Products: